We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.39%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.6M
AUM Growth
-$2.33B
Cap. Flow
-$744M
Cap. Flow %
-28,550.23%
Top 10 Hldgs %
59.11%
Holding
341
New
89
Increased
83
Reduced
62
Closed
85

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$32.4M
2
AZN icon
AstraZeneca
AZN
+$11.6M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$10.4M
4
QRHC icon
Quest Resource Holding
QRHC
+$8.96M
5
MBOT icon
Microbot Medical
MBOT
+$7.86M

Top Sells

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$64.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$53.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$13.3M
5
OPK icon
Opko Health
OPK
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 6.33%
2 Energy 0.47%
3 Consumer Discretionary 0.36%
4 Industrials 0.15%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
CALL
Vertex Pharmaceuticals
VRTX
$123B
$255K 9.78%
22,669
-7,167
-24% -$682K
GILD icon
2
PUT
Gilead Sciences
GILD
$165B
$147K 5.64%
13,803
+4,147
+43% +$406K
BIIB icon
3
CALL
Biogen
BIIB
$30.9B
$138K 5.31%
4,180
+692
+20% +$228K
VRTX icon
4
PUT
Vertex Pharmaceuticals
VRTX
$123B
$108K 4.14%
9,592
-374
-4% -$35.6K
SPY icon
5
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$86.4K 3.32%
+4,386
New +$867K
ACHC icon
6
CALL
Acadia Healthcare
ACHC
$2.55B
$69.5K 2.67%
+28,073
New +$1.37M
OEF icon
7
PUT
iShares S&P 100 ETF
OEF
$19.5B
$57.8K 2.22%
5,289
+1,123
+27% +$98.9K
AGN
8
PUT
DELISTED
Allergan plc
AGN
$48.4K 1.86%
2,008
+1,258
+168% +$282K
BMY icon
9
CALL
Bristol-Myers Squibb
BMY
$129B
$46.7K 1.79%
9,134
+7,721
+546% +$386K
ABBV icon
10
CALL
AbbVie
ABBV
$465B
$43.9K 1.69%
7,607
-5,294
-41% -$294K
AZN icon
11
PUT
AstraZeneca
AZN
$269B
$40.4K 1.55%
4,639
+3,647
+368% +$267K
MRK icon
12
CALL
Merck
MRK
$322B
$37.5K 1.44%
+6,623
New +$372K
AGN
13
CALL
DELISTED
Allergan plc
AGN
$37K 1.42%
1,533
+758
+98% +$170K
A icon
14
CALL
Agilent Technologies
A
$39.6B
$28.7K 1.1%
+7,033
New +$287K
LLY icon
15
CALL
Eli Lilly
LLY
$1.08T
$28.3K 1.09%
+4,359
New +$276K
TSLA icon
16
PUT
Tesla
TSLA
$1.18T
$28.2K 1.08%
17,415
+2,490
+17% +$41.1K
CELG
17
PUT
DELISTED
Celgene Corp
CELG
$26K 1%
2,748
-378
-12% -$34.1K
GILD icon
18
CALL
Gilead Sciences
GILD
$165B
$24.4K 0.94%
2,288
-718
-24% -$70.3K
IOC
19
PUT
DELISTED
Interoil Corporation
IOC
$23.6K 0.91%
4,350
+983
+29% +$57.3K
CELG
20
CALL
DELISTED
Celgene Corp
CELG
$22K 0.84%
2,320
-948
-29% -$85.6K
MNKD icon
21
CALL
MannKind Corp
MNKD
$1.19B
$19.8K 0.76%
6,688
+2,085
+45% +$82.3K
OPK icon
22
CALL
Opko Health
OPK
$1.02B
$19K 0.73%
22,323
-338
-1% -$2.97K
AZN icon
23
CALL
AstraZeneca
AZN
$269B
$18.9K 0.72%
1,503
+351
+30% +$25.7K
ALNY icon
24
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
$18.4K 0.71%
2,355
+2,260
+2,379% +$146K
MDVN
25
CALL
DELISTED
MEDIVATION, INC.
MDVN
$17.7K 0.68%
+3,576
New +$152K
1
2 3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q3 2014 Portfolio in Review

As of Q3 2014, Sabby Management held 341 positions worth $2.6M, down 100% from $2.33B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $744M in Q3 2014, closing 85 positions and reducing 62 holdings. Its most notable exit was Weyerhaeuser, an estimated $64.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Acadia Healthcare worth $16.4K.

  • Sabby Management's largest Q3 2014 buy was Acadia Healthcare: 663,324 shares worth $16.4K.
  • Sabby Management added most to AstraZeneca in Q3 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $6.87M.
  • Sabby Management fully exited Weyerhaeuser in Q3 2014, selling an estimated $64.6M.
  • Sabby Management's ten largest holdings make up 59% of its $2.6M portfolio in Q3 2014.
  • Sabby Management opened 89 new positions and closed 85 in Q3 2014.
  • Sabby Management's portfolio value fell 100% quarter-over-quarter to $2.6M.

Based on Sabby Management's 13F filing for Q3 2014, filed 14 Nov 2014.